PDF
File
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Phase Holographic Imaging (PHI) is pleased to announce a strategic activity schedule for spring 2024, during which PHI will participate in select industry webinars and events. PHI's initiatives aim to foster collaboration and reinforce PHI's role as a thought leader for creating standardized cell quality control in regenerative medicine by connecting with leading professionals, researchers, and innovators to support knowledge exchange and partnership opportunities.
As previously communicated, PHI has joined the International Alliance for Regenerative Medicine (ARM) (https://alliancerm.org/), an organization that advocates for cell and genetic therapies and is represented by 475 members in 25 countries. The organization promotes collaboration between scientists, healthcare professionals, and industry to advance the development of advanced therapy medicinal products (ATMPs) and organizes several international conferences throughout the year.
[image]
Cell & Gene Meeting on the Mediterranean (Rome, April 9-11)
PHI will begin its spring activities with attendance at ARM's leading conference, "Cell & Gene Meeting on the Mediterranean (https://meetingonthemed.com/)", in Rome from April 9-11. This conference serves as an important forum for the European cell and gene therapy community, exploring a broad range of commercialization-related topics. Participants will discuss market entry strategies, regulatory considerations, manufacturing issues, and financial planning in the industry. Representing PHI, CSO Kersti Alm will introduce PHI and highlight the advantages of PHI's innovative Quantitative Phase Imaging (QPI) technology, discussing its applications for advanced cell quality control in cell therapy manufacturing.
[image]
RegMIC annual meeting (Charlotte, NC, May 15)
On May 15, PHI will attend the RegMIC annual meeting (https://remdo.org/2024-regmic-annual-meeting-registration/) in Charlotte, North Carolina. The Regenerative Manufacturing Innovation Consortium (RegMIC) is a non-profit organization committed to accelerating the development and commercialization of regenerative medicine therapies. The meeting will convene industry leaders, researchers, and innovators to explore the latest advancements and opportunities in regenerative medicine. As a RegMIC member, a PHI delegation will be there to advocate for QPI technology in standardized cell quality control measurements and engage with the regenerative medicine community to drive collaborations and commercialization activities.